Lantheus Medical Imaging parent company Lantheus Holdings announced the results of its Benefit 1 clinical trial, which evaluated the potential advantages of using its Definity ultrasound contrast agent to evaluate heart failure.
The trial results indicated that contrast-enhanced echocardiography led to statistically significant improvements in measurements of left ventricular diastolic and systolic blood flow as well as stroke volume for the 145 trial participants, compared with unenhanced echocardiography and cardiac MRI.
However, contrast-enhanced echocardiography did not produce any notable improvements to measurement accuracy or interreader variability for left ventricular ejection fraction.
"When the data from Benefit 2 are available, we will compile the datasets to analyze the full results of the trials," Lantheus Chief Medical Officer Dr. Istvan Molnar said in a statement.
